Catalyst Event
Guardant Health Inc (GH) · Other
From Akros SCHK HK-Global Genomics Index (ASHGGENM)
4/28/2026, 12:00:00 AM
Stock price declined approximately 5% on April 28, 2026, after the FDA released briefing documents expressing concerns about the trial design for AstraZeneca's camizestrant, which uses Guardant's G360 test.
Korean Translation
2026년 4월 28일, 가던트의 G360 테스트를 사용하는 아스트라제네카의 카미제스트란트 임상 설계에 대한 FDA의 우려 표명 문건 발표 이후 주가가 약 5% 하락함.
Related Recent Events
Livzon Pharmaceutical Group Inc (1513) · Other
Ex-dividend date for the final dividend of RMB 1.43 per share for the fiscal year 2025 on 2026-06-16, scheduled.
6/16/2026, 12:00:00 AM
Biocytogen Pharmaceuticals (Beijing) Co Ltd (2315) · Other
Annual General Meeting to be held on 2026-05-21 to review reports and approve plans; routine meetings typically have a 1-5% price impact, scheduled
5/21/2026, 12:00:00 AM
Shanghai Fosun Pharmaceutical (Group) Co Ltd (2196) · Other
An earnings briefing for the 2025 fiscal year and Q1 2026 results is scheduled for May 14, 2026. This routine communication event is estimated to have a price impact of at least 1% scheduled.
5/14/2026, 12:00:00 AM
Caris Life Sciences Inc (CAI) · Earnings Release
Caris Life Sciences to report first quarter 2026 financial results on May 7, 2026, scheduled.
5/7/2026, 12:00:00 AM
Guardant Health Inc (GH) · Earnings Release
Guardant Health is scheduled to release its Q1 2026 financial results after market close on May 7, 2026. Analysts forecast EPS of ($0.47) and revenue of $279.17 million. High importance estimated due to potential for significant volatility following earnings results, scheduled.
5/7/2026, 12:00:00 AM
Natera Inc (NTRA) · Earnings Release
Natera is scheduled to release its first quarter 2026 financial results after the market closes on May 7, 2026, with analysts forecasting revenue of approximately $617.5 million and an EPS of -$0.55; high importance is expected due to typical earnings volatility, scheduled.
5/7/2026, 12:00:00 AM